Angiotensin II receptor blocker intake associates with reduced markers of inflammatory activation and decreased mortality in patients with cardiovascular comorbidities and COVID-19 disease
<h4>Aims</h4> Patients with cardiovascular comorbidities have a significantly increased risk for a critical course of COVID-19. As the SARS-CoV2 virus enters cells via the angiotensin-converting enzyme receptor II (ACE2), drugs which interact with the renin angiotensin aldosterone system...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/b5baff8de9bf4e33b669346990756db5 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:b5baff8de9bf4e33b669346990756db5 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:b5baff8de9bf4e33b669346990756db52021-11-04T06:07:17ZAngiotensin II receptor blocker intake associates with reduced markers of inflammatory activation and decreased mortality in patients with cardiovascular comorbidities and COVID-19 disease1932-6203https://doaj.org/article/b5baff8de9bf4e33b669346990756db52021-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8530317/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Aims</h4> Patients with cardiovascular comorbidities have a significantly increased risk for a critical course of COVID-19. As the SARS-CoV2 virus enters cells via the angiotensin-converting enzyme receptor II (ACE2), drugs which interact with the renin angiotensin aldosterone system (RAAS) were suspected to influence disease severity. <h4>Methods and results</h4> We analyzed 1946 consecutive patients with cardiovascular comorbidities or hypertension enrolled in one of the largest European COVID-19 registries, the Lean European Open Survey on SARS-CoV-2 (LEOSS) registry. Here, we show that angiotensin II receptor blocker intake is associated with decreased mortality in patients with COVID-19 [OR 0.75 (95% CI 0,59–0.96; p = 0.013)]. This effect was mainly driven by patients, who presented in an early phase of COVID-19 at baseline [OR 0,64 (95% CI 0,43–0,96; p = 0.029)]. Kaplan-Meier analysis revealed a significantly lower incidence of death in patients on an angiotensin receptor blocker (ARB) (n = 33/318;10,4%) compared to patients using an angiotensin-converting enzyme inhibitor (ACEi) (n = 60/348;17,2%) or patients who received neither an ACE-inhibitor nor an ARB at baseline in the uncomplicated phase (n = 90/466; 19,3%; p<0.034). Patients taking an ARB were significantly less frequently reaching the mortality predicting threshold for leukocytes (p<0.001), neutrophils (p = 0.002) and the inflammatory markers CRP (p = 0.021), procalcitonin (p = 0.001) and IL-6 (p = 0.049). ACE2 expression levels in human lung samples were not altered in patients taking RAAS modulators. <h4>Conclusion</h4> These data suggest a beneficial effect of ARBs on disease severity in patients with cardiovascular comorbidities and COVID-19, which is linked to dampened systemic inflammatory activity.Sebastian CremerLisa PilgramAlexander BerkowitschMelanie StecherSiegbert RiegMariana ShumliakivskaDenisa BojkovaJulian Uwe Gabriel WagnerGalip Servet AslanChristoph SpinnerGuillermo LuxánFrank HansesSebastian DolffChristiane PiepelClemens RuppertAndreas GuentherMaria Madeleine RüthrichJörg Janne VehreschildKai WilleMartina HaselbergerHanno HeuzerothArne HansenThomas EschenhagenJindrich CinatlSandra CiesekStefanie DimmelerStefan BorgmannAndreas Zeiheron behalf of the LEOSS study groupPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 10 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Sebastian Cremer Lisa Pilgram Alexander Berkowitsch Melanie Stecher Siegbert Rieg Mariana Shumliakivska Denisa Bojkova Julian Uwe Gabriel Wagner Galip Servet Aslan Christoph Spinner Guillermo Luxán Frank Hanses Sebastian Dolff Christiane Piepel Clemens Ruppert Andreas Guenther Maria Madeleine Rüthrich Jörg Janne Vehreschild Kai Wille Martina Haselberger Hanno Heuzeroth Arne Hansen Thomas Eschenhagen Jindrich Cinatl Sandra Ciesek Stefanie Dimmeler Stefan Borgmann Andreas Zeiher on behalf of the LEOSS study group Angiotensin II receptor blocker intake associates with reduced markers of inflammatory activation and decreased mortality in patients with cardiovascular comorbidities and COVID-19 disease |
| description |
<h4>Aims</h4> Patients with cardiovascular comorbidities have a significantly increased risk for a critical course of COVID-19. As the SARS-CoV2 virus enters cells via the angiotensin-converting enzyme receptor II (ACE2), drugs which interact with the renin angiotensin aldosterone system (RAAS) were suspected to influence disease severity. <h4>Methods and results</h4> We analyzed 1946 consecutive patients with cardiovascular comorbidities or hypertension enrolled in one of the largest European COVID-19 registries, the Lean European Open Survey on SARS-CoV-2 (LEOSS) registry. Here, we show that angiotensin II receptor blocker intake is associated with decreased mortality in patients with COVID-19 [OR 0.75 (95% CI 0,59–0.96; p = 0.013)]. This effect was mainly driven by patients, who presented in an early phase of COVID-19 at baseline [OR 0,64 (95% CI 0,43–0,96; p = 0.029)]. Kaplan-Meier analysis revealed a significantly lower incidence of death in patients on an angiotensin receptor blocker (ARB) (n = 33/318;10,4%) compared to patients using an angiotensin-converting enzyme inhibitor (ACEi) (n = 60/348;17,2%) or patients who received neither an ACE-inhibitor nor an ARB at baseline in the uncomplicated phase (n = 90/466; 19,3%; p<0.034). Patients taking an ARB were significantly less frequently reaching the mortality predicting threshold for leukocytes (p<0.001), neutrophils (p = 0.002) and the inflammatory markers CRP (p = 0.021), procalcitonin (p = 0.001) and IL-6 (p = 0.049). ACE2 expression levels in human lung samples were not altered in patients taking RAAS modulators. <h4>Conclusion</h4> These data suggest a beneficial effect of ARBs on disease severity in patients with cardiovascular comorbidities and COVID-19, which is linked to dampened systemic inflammatory activity. |
| format |
article |
| author |
Sebastian Cremer Lisa Pilgram Alexander Berkowitsch Melanie Stecher Siegbert Rieg Mariana Shumliakivska Denisa Bojkova Julian Uwe Gabriel Wagner Galip Servet Aslan Christoph Spinner Guillermo Luxán Frank Hanses Sebastian Dolff Christiane Piepel Clemens Ruppert Andreas Guenther Maria Madeleine Rüthrich Jörg Janne Vehreschild Kai Wille Martina Haselberger Hanno Heuzeroth Arne Hansen Thomas Eschenhagen Jindrich Cinatl Sandra Ciesek Stefanie Dimmeler Stefan Borgmann Andreas Zeiher on behalf of the LEOSS study group |
| author_facet |
Sebastian Cremer Lisa Pilgram Alexander Berkowitsch Melanie Stecher Siegbert Rieg Mariana Shumliakivska Denisa Bojkova Julian Uwe Gabriel Wagner Galip Servet Aslan Christoph Spinner Guillermo Luxán Frank Hanses Sebastian Dolff Christiane Piepel Clemens Ruppert Andreas Guenther Maria Madeleine Rüthrich Jörg Janne Vehreschild Kai Wille Martina Haselberger Hanno Heuzeroth Arne Hansen Thomas Eschenhagen Jindrich Cinatl Sandra Ciesek Stefanie Dimmeler Stefan Borgmann Andreas Zeiher on behalf of the LEOSS study group |
| author_sort |
Sebastian Cremer |
| title |
Angiotensin II receptor blocker intake associates with reduced markers of inflammatory activation and decreased mortality in patients with cardiovascular comorbidities and COVID-19 disease |
| title_short |
Angiotensin II receptor blocker intake associates with reduced markers of inflammatory activation and decreased mortality in patients with cardiovascular comorbidities and COVID-19 disease |
| title_full |
Angiotensin II receptor blocker intake associates with reduced markers of inflammatory activation and decreased mortality in patients with cardiovascular comorbidities and COVID-19 disease |
| title_fullStr |
Angiotensin II receptor blocker intake associates with reduced markers of inflammatory activation and decreased mortality in patients with cardiovascular comorbidities and COVID-19 disease |
| title_full_unstemmed |
Angiotensin II receptor blocker intake associates with reduced markers of inflammatory activation and decreased mortality in patients with cardiovascular comorbidities and COVID-19 disease |
| title_sort |
angiotensin ii receptor blocker intake associates with reduced markers of inflammatory activation and decreased mortality in patients with cardiovascular comorbidities and covid-19 disease |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2021 |
| url |
https://doaj.org/article/b5baff8de9bf4e33b669346990756db5 |
| work_keys_str_mv |
AT sebastiancremer angiotensiniireceptorblockerintakeassociateswithreducedmarkersofinflammatoryactivationanddecreasedmortalityinpatientswithcardiovascularcomorbiditiesandcovid19disease AT lisapilgram angiotensiniireceptorblockerintakeassociateswithreducedmarkersofinflammatoryactivationanddecreasedmortalityinpatientswithcardiovascularcomorbiditiesandcovid19disease AT alexanderberkowitsch angiotensiniireceptorblockerintakeassociateswithreducedmarkersofinflammatoryactivationanddecreasedmortalityinpatientswithcardiovascularcomorbiditiesandcovid19disease AT melaniestecher angiotensiniireceptorblockerintakeassociateswithreducedmarkersofinflammatoryactivationanddecreasedmortalityinpatientswithcardiovascularcomorbiditiesandcovid19disease AT siegbertrieg angiotensiniireceptorblockerintakeassociateswithreducedmarkersofinflammatoryactivationanddecreasedmortalityinpatientswithcardiovascularcomorbiditiesandcovid19disease AT marianashumliakivska angiotensiniireceptorblockerintakeassociateswithreducedmarkersofinflammatoryactivationanddecreasedmortalityinpatientswithcardiovascularcomorbiditiesandcovid19disease AT denisabojkova angiotensiniireceptorblockerintakeassociateswithreducedmarkersofinflammatoryactivationanddecreasedmortalityinpatientswithcardiovascularcomorbiditiesandcovid19disease AT julianuwegabrielwagner angiotensiniireceptorblockerintakeassociateswithreducedmarkersofinflammatoryactivationanddecreasedmortalityinpatientswithcardiovascularcomorbiditiesandcovid19disease AT galipservetaslan angiotensiniireceptorblockerintakeassociateswithreducedmarkersofinflammatoryactivationanddecreasedmortalityinpatientswithcardiovascularcomorbiditiesandcovid19disease AT christophspinner angiotensiniireceptorblockerintakeassociateswithreducedmarkersofinflammatoryactivationanddecreasedmortalityinpatientswithcardiovascularcomorbiditiesandcovid19disease AT guillermoluxan angiotensiniireceptorblockerintakeassociateswithreducedmarkersofinflammatoryactivationanddecreasedmortalityinpatientswithcardiovascularcomorbiditiesandcovid19disease AT frankhanses angiotensiniireceptorblockerintakeassociateswithreducedmarkersofinflammatoryactivationanddecreasedmortalityinpatientswithcardiovascularcomorbiditiesandcovid19disease AT sebastiandolff angiotensiniireceptorblockerintakeassociateswithreducedmarkersofinflammatoryactivationanddecreasedmortalityinpatientswithcardiovascularcomorbiditiesandcovid19disease AT christianepiepel angiotensiniireceptorblockerintakeassociateswithreducedmarkersofinflammatoryactivationanddecreasedmortalityinpatientswithcardiovascularcomorbiditiesandcovid19disease AT clemensruppert angiotensiniireceptorblockerintakeassociateswithreducedmarkersofinflammatoryactivationanddecreasedmortalityinpatientswithcardiovascularcomorbiditiesandcovid19disease AT andreasguenther angiotensiniireceptorblockerintakeassociateswithreducedmarkersofinflammatoryactivationanddecreasedmortalityinpatientswithcardiovascularcomorbiditiesandcovid19disease AT mariamadeleineruthrich angiotensiniireceptorblockerintakeassociateswithreducedmarkersofinflammatoryactivationanddecreasedmortalityinpatientswithcardiovascularcomorbiditiesandcovid19disease AT jorgjannevehreschild angiotensiniireceptorblockerintakeassociateswithreducedmarkersofinflammatoryactivationanddecreasedmortalityinpatientswithcardiovascularcomorbiditiesandcovid19disease AT kaiwille angiotensiniireceptorblockerintakeassociateswithreducedmarkersofinflammatoryactivationanddecreasedmortalityinpatientswithcardiovascularcomorbiditiesandcovid19disease AT martinahaselberger angiotensiniireceptorblockerintakeassociateswithreducedmarkersofinflammatoryactivationanddecreasedmortalityinpatientswithcardiovascularcomorbiditiesandcovid19disease AT hannoheuzeroth angiotensiniireceptorblockerintakeassociateswithreducedmarkersofinflammatoryactivationanddecreasedmortalityinpatientswithcardiovascularcomorbiditiesandcovid19disease AT arnehansen angiotensiniireceptorblockerintakeassociateswithreducedmarkersofinflammatoryactivationanddecreasedmortalityinpatientswithcardiovascularcomorbiditiesandcovid19disease AT thomaseschenhagen angiotensiniireceptorblockerintakeassociateswithreducedmarkersofinflammatoryactivationanddecreasedmortalityinpatientswithcardiovascularcomorbiditiesandcovid19disease AT jindrichcinatl angiotensiniireceptorblockerintakeassociateswithreducedmarkersofinflammatoryactivationanddecreasedmortalityinpatientswithcardiovascularcomorbiditiesandcovid19disease AT sandraciesek angiotensiniireceptorblockerintakeassociateswithreducedmarkersofinflammatoryactivationanddecreasedmortalityinpatientswithcardiovascularcomorbiditiesandcovid19disease AT stefaniedimmeler angiotensiniireceptorblockerintakeassociateswithreducedmarkersofinflammatoryactivationanddecreasedmortalityinpatientswithcardiovascularcomorbiditiesandcovid19disease AT stefanborgmann angiotensiniireceptorblockerintakeassociateswithreducedmarkersofinflammatoryactivationanddecreasedmortalityinpatientswithcardiovascularcomorbiditiesandcovid19disease AT andreaszeiher angiotensiniireceptorblockerintakeassociateswithreducedmarkersofinflammatoryactivationanddecreasedmortalityinpatientswithcardiovascularcomorbiditiesandcovid19disease AT onbehalfoftheleossstudygroup angiotensiniireceptorblockerintakeassociateswithreducedmarkersofinflammatoryactivationanddecreasedmortalityinpatientswithcardiovascularcomorbiditiesandcovid19disease |
| _version_ |
1718445171274678272 |